Following the common terminology criteria for adverse events (CTCAE v5.0), 8/17 patients (47.1%) maintained the same grade of thrombocytopenia after one cycle of [177Lu]Lu-PSMA-617 administration, 5/17 patients (29.4%) showed an improvement resulting in a lower CTCAE score, while 4/17 patients (23.5%) progressed to a higher grade (Fig. 3). Here, FOLH1 is linked to Thrombocytopenia.